ITIrēna Teterina

Irēna Teterina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irēna Teterina has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksejs Princevs

    Clinic for Dermatology and Sexually Transmitted Diseases, Riga 1st Hospital, Rīga, Latvia

    1 shared publication
  • Dins Smits

    Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia

    1 shared publication
  • Eva Petrošina

    Faculty of Medicine , Rīga Stradiņš University , 16 Dzirciema Str., Rīga, LV-1007 , Latvia

    1 shared publication
  • Ilona Hartmane

    Department of Dermatology and Venereology, Faculty of Medicine, Riga Stradins University, LV-1010 Riga, Latvia

    1 shared publication
  • Ingmars Mikazans

    Clinic for Dermatology and Sexually Transmitted Diseases, Riga 1st Hospital, Rīga, Latvia

    1 shared publication
  • Iveta Ivdra

    Clinic for Dermatology and Sexually Transmitted Diseases, Riga 1st Hospital, Rīga, Latvia

    1 shared publication

Latest Publications

  • Open Access

    National 30-Day Readmission Trends in IBD 2014–2020—Are We Aiming for Improvement?

    by Irēna Teterina, Veronika Mirzajanova, Viktorija Mokricka, Maksims Zolovs, Dins Šmits, Juris Pokrotnieks

    Background: Inflammatory bowel disease (IBD) prevalence in Eastern Europe is increasing. The 30-day readmission rate is a crucial quality metric in healthcare, reflecting the effectiveness of initial treatment and the continuity of care post-discharge; however, such parameters are rarely analyzed. The aim of this study was to explore the trends in 30-day readmissions among patients with inflammatory bowel disease in Latvia between 2014 and 2020. Methods: This is a retrospective trends study in IBD—ulcerative colitis and Crohn’s disease (UC and CD)—patients in Latvia between 2014 and 2020, involving all IBD patients identified in the National Health service database in the International Classification of Diseases-10 (ICD) classification (K50.X and K51.X) and having at least one prescription for IBD diagnoses. We assessed all IBD-related hospitalizations (discharge ICD codes K50X and K51X), as well as hospitalizations potentially related to IBD comorbidities. We analyzed hospitalization trends and obtained the 30 day all-cause readmission rate, disease specific readmission rate and readmission proportion for specific calendar years. Trends in readmissions and the mean length of stay (LOS) for CD and UC were calculated. Results: Despite a decrease in admission rates observed in 2020, the total number of readmissions for CD and UC has increased. Female patients prevailed through the study period and were significantly older than male patients in both the CD and UC groups, p < 0.05. We noted that there was no trend for 30 day all-cause readmission rate for CD (p > 0.05); however, there was a statistically significant trend for 30 day all-cause readmission for UC patients (p-trend = 0.018) in the period from 2014 to 2019. There was a statistically significant trend for CD-specific readmission rate (p < 0.05); however, no statistically significant trend was observed for UC-specific readmission (p > 0.05). An exploratory analysis did not reveal any statistically significant differences between treated and not-treated IBD patients (p > 0.05). The increasing trend is statistically significant over the period 2014–2018 (p < 0.05); however, the trend interrupts in 2020, which can be associated with the COVID-19 global pandemic and the related changes in admission flows where the gastroenterology capacity was reallocated to accommodate increasing numbers of COVID-19 patients. More studies are needed to evaluate the long-term impact of COVID-19 pandemic and 30-day readmissions. No significant dynamics were observed in the mean total hospitalization costs over the 2014–2020 period.


  • Use of ceftriaxone as an alternative treatment method in pregnant women diagnosed with syphilis – a single centre experience

    by Ilona Hartmane, Iveta Ivdra, Ingmars Mikazans, Aleksejs Princevs, Irena Teterina, Vanda Bondare-Ansberga, Lelde Reinberga

    Background: There are few data on the use of ceftriaxone in pregnant women diagnosed with syphilis. The aim of this study was to investigate the safety and efficacy of ceftriaxone as an alternative treatment option for syphilis during pregnancy. Methods: A retrospective analysis of 79 pregnant women diagnosed with syphilis and treated with ceftriaxone was conducted. Results: No cases of intolerance, Jarisch-Herxheimer reactions, or allergic reactions were recorded. The average time to seronegativation for secondary syphilis with symptoms was 6.14 months ± 2.76, and for latent forms, it was 7.52 months ± 1.84. Patients received no additional treatment. No serious adverse drug reactions were reported. Conclusions: Data from our study support the use of ceftriaxone as an effective and safe alternative treatment for pregnant women diagnosed with syphilis when penicillin therapy is contraindicated or unavailable.


  • Open Access

    Burden of extraintestinal manifestations and comorbidities in treated and untreated ulcerative colitis and Crohn’s disease: a Latvian nationwide prescription database study 2014–2019

    by Irēna Teterina, Viktorija Mokricka, Eva Petrošina, Juris Pokrotnieks

    Inflammatory bowel diseases (IBD) are frequently accompanied by extraintestinal manifestations (EIMs) due to systemic autoimmune processes, which are important in the management of IBD patients and their long-term outcomes. The aim of the study was to determine the occurrence of EIMs comorbidities and their burden in IBD patients, based on the Latvian nationwide reimbursed prescription database from 2012 till 2019. Incident Crohn’s disease (CD) and ulcerative colitis (UC) patients between 2014 and 2018 were matched on age and sex with non-treated IBD controls and followed up until 2019. EIMs were selected based on a previously used methodology and grouped into organ systems. The cohort was tested for differences in the timing and occurrence of EIMs, as well as overall cumulating disease burden. The study population included 187 CD and 1137 UC patients. Higher prevalence of EIMs was observed in untreated IBD patients, whereas in the treated IBD patient group prevalence remained numerically similar. Among treated patients, the most common EIMs affected cardiovascular, hepatopancreatobiliary, endocrine, musculoskeletal, respiratory, and the skin and intestinal tract systems, where 28.4–79.9% of IBD patients experienced these EIMs for the first time before their IBD diagnosis. The treated female IBD patients tended to have higher frequency of EIMs compared to male patients. The overall comorbidity burden trend increased with time. The study provides evidence that treated IBD patients have lower risk for EIMs/comorbidities compared to untreated IBD patients.